HYDERABAD, India & BOSTON--(BUSINESS WIRE)--#Analytics--Excelra, a leading global Data and Analytics provider for Life Science organizations, has announced a strategic majority investment in Anlitiks, a young and rapidly growing technology company in the value and evidence domain.

The investment reinforces Excelra�s push into the Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) analytics area. This deal is a testimony to Excelra�s commitment to drug discovery and commercialization by combining deep scientific domain expertize with cutting-edge technology and analytics solutions.

Anlitiks, headquartered in Boston, is a HEOR and RWE company, founded by Kannan Rajagopalan, a technology entrepreneur. According to Kannan, Anlitiks� mission is to help Life Sciences organizations translate real-world data rapidly into value evidence, using a unique data + platform + service approach. The engine driving the business is Anlitiks� RapidAnalyzer�, a flexible, data-agnostic platform that captures the entire lifecycle of HEOR/RWE from hypothesis, data integration, analysis, visualization to a research report. RapidAnalyzer� changes the competitive landscape by drastically reducing the time taken to gain valuable insights on large-scale data from months to just a matter of weeks.

As President and Chief Scientific Officer at Anlitiks, Dr. Krithika (Kitty) Rajagopalan, an industry veteran and well-published HEOR, RWE, Pricing, and Market Access executive, helps provide leadership and direction in defining reimbursable strategies for biopharmaceutical organizations.

Anandbir Brar, Chief Executive Officer at Excelra, mentioned, "Anlitiks has a unique platform + consulting business model, combining highly skilled and experienced HEOR experts, and an integrated platform - RapidAnalyzer� that helps execute large volumes of analytical workflows. Our combined strength empowers Life Science organizations with accelerated yet informed decision-making."

Data and Digital transformation have become a strategic imperative for the Life Sciences industry to break down silos between multi-omics, clinical trials, and real-world data. The partnership with Anlitiks augments Excelra�s vision to use domain-led data science to empower innovation from discovery to market.

Kannan Rajagopalan stated, �Our vision is to be a technology-enabled disruptive force in generating rapid actionable insights for the Life Science industry using real-world data. Excelra�s focus areas dovetail perfectly with our growth strategy, making it the beginning of an exciting journey.�

About Excelra

Excelra�s data and analytics solutions empower innovation in life sciences from discovery to market. The Excelra edge comes from harmonizing heterogeneous data sets and applying innovative bioinformatics know-how and technologies to accelerate drug discovery & development with reliable and result-oriented insights.

For more information, visit https://www.excelra.com

About Anlitiks

Anlitiks is a leading healthcare analytics� organization dedicated to translating real-world data into value evidence by employing a unique data-agnostic platform-service model.

To know more, visit www.anlitiks.com

Contacts

Jigesh Shah

[email protected]